| Referências: |
1. Neuman MG, Nanau RM. Inflammatory bowel disease: role of diet, microbiota, life style. Translational Research. Volume 160 (1); 29-44, 2012.
2. de Andrade KG, et. al. Oxidative Stress and Inflammation in Hepatic Diseases: Therapeutic Possibilities of N-Acetylcysteine. Int. J. Mol. Sci. 2015, 16, 30269–30308
3. Moura FA, et. al. Antioxidant therapy for treatment of inflammatory bowel disease: Does it work? Redox Biology, 6 (2015): 617–639;
4. Sartor, R.B. Therapeutic manipulation of the enteric microflora ininflammatory bowel diseases: antibiotics, probiotics, andprebiotics, Gastroenterology, 126(6 )(2004)1620–1633;
5. Rezaie A, Parker RD, Abdollahi M. Oxidative stress and pathogenesis of inflammatory bowel disease: an epiphenomenon or the cause? Dig.Dis.Sci., 52 (9)(2007)2015–2021;
6. Loman BR, et. al. Prebiotic and probiotic treatment of nonalcoholic fatty liver disease: a systematic review and meta-analysis. Nutrition Reviews VR, Vol. 0(0):1–18;
7. Zhu L, et. al. Gut microbiome and nonalcoholic fatty liver diseases. Pediatric Research, vol 77 (1), 245-251. |
